Cassava Announces Closure of U.S. Department of Justice Investigation
Rhea-AI Summary
Cassava Sciences (NASDAQ: SAVA) announced that the U.S. Department of Justice Fraud Section has closed its inquiry into the company related to allegations in United States v. Wang.
The indictment was dismissed with prejudice on October 23, 2025. Cassava previously reached an SEC settlement in September 2024 and paid a monetary penalty without admitting or denying the SEC's allegations. The company says it cooperated fully and will continue focusing on developing a treatment for TSC-related epilepsy.
Positive
- DOJ inquiry officially closed by Fraud Section
- Indictment dismissed with prejudice on October 23, 2025
- Company cooperated fully with DOJ and SEC investigations
Negative
- SEC negligence-based disclosure charges led to monetary penalty in September 2024
- Company was subject to a criminal indictment prior to dismissal
News Market Reaction – SAVA
On the day this news was published, SAVA gained 1.88%, reflecting a mild positive market reaction. Argus tracked a peak move of +7.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $103M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
SAVA was up 1.91% while peers showed mixed moves: HLVX (-0.48%), ANRO (-6.45%), MGNX (+0.59%), PLRX (+10.62%), SPRO (-0.85%). This pattern suggests a stock-specific response rather than a coordinated biotechnology sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Phase 3 results | Negative | -3.3% | Phase 3 Alzheimer’s trials failed all endpoints; Alzheimer’s program discontinued. |
| Dec 23 | Litigation settlement | Negative | -7.6% | Agreement to settle consolidated securities class action for $31.25M. |
| Nov 12 | Earnings and update | Positive | +4.8% | Q3 2025 results with narrowed loss, lower R&D, and TSC epilepsy PoC plans. |
| Oct 22 | Board appointment | Positive | -7.0% | Appointment of experienced biopharma executive to board to support TSC strategy. |
| Aug 25 | Conference participation | Neutral | -1.8% | Announcement of presentation at H.C. Wainwright global investment conference. |
Recent news has mostly seen price moves align with the apparent positive or negative tone, with only one notable divergence on a management appointment.
Over the last six months, Cassava has moved from Alzheimer’s failure toward TSC‑related epilepsy, while working through significant legal and regulatory issues. A Jan 13, 2026 update confirmed Phase 3 Alzheimer’s trials failed endpoints and the program was discontinued. In Dec 2025, the company agreed to a $31.25M securities class action settlement and later reported Q3 2025 results showing sharply lower R&D as Alzheimer’s spending wound down. The latest DOJ closure and prior SEC settlement continue resolving legacy legal overhangs as Cassava refocuses on CNS indications.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 12, 2025 allows Cassava to offer up to $200,000,000 in various securities, including an at-the-market component of up to $50,000,000 in common stock. Proceeds are designated for general corporate purposes and working capital, providing flexibility for future financing.
Market Pulse Summary
This announcement marked the formal end of federal investigations into Cassava, with the DOJ Fraud Section closing its inquiry following an indictment dismissal and the SEC matter already settled. It removed a major legal overhang as the company pivoted toward TSC‑related epilepsy. In parallel, Cassava maintained a sizeable $200,000,000 shelf registration, giving it broad financing flexibility. Investors monitoring this story would likely focus on future trial progress, additional regulatory interactions, and any use of the shelf for funding.
Key Terms
u.s. department of justice fraud section regulatory
u.s. securities and exchange commission regulatory
indictment regulatory
dismissed with prejudice regulatory
tuberous sclerosis complex (tsc) medical
epilepsy medical
AI-generated analysis. Not financial advice.
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.
As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC’s allegations.
The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.
“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” said Richard J. Barry, President and Chief Executive Officer of Cassava.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Investors
Sandya von der Weid
svonderweid@lifesciadvisors.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com
IR@cassavasciences.com
Cautionary Note Regarding Forward-Looking Statements: add a few notes on the paper
This news release contains forward-looking statements. Forward-looking statements may be identified by words such as “anticipate”, “before”, “believe”, “could”, “expect”, “forecast”, “intend”, “may”, ”pending”, “plan”, “possible”, “potential”, “prepares for”, “will”, and other words and terms of similar meaning.
Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks inherent in drug discovery and development or specific to Cassava Sciences, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the period ended September 30, 2025, and subsequent reports periodically filed and to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at www.sec.gov.
All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.
Our clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.
We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and any other SEC filings in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.
FAQ
What did Cassava (SAVA) announce about the DOJ investigation on February 19, 2026?
Was the indictment against Cassava (SAVA) resolved and when was it dismissed?
What was the outcome of the SEC matter involving Cassava (SAVA)?
Does the DOJ closure mean all investigations into Cassava (SAVA) are finished?
How will the DOJ closure affect Cassava's (SAVA) focus on its drug programs?
Did Cassava (SAVA) admit wrongdoing in the SEC settlement?
